ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12).
Company Details
- Founded
- -
- Address
- 575 Chesapeake Drive, Redwood City,ca 94063,united States
- Industry
- Biotechnology
- Website
- http://www.armobio.com/index.php
- Keywords
- Immuno-Oncology.
- HQ
- Redwood City, CA
Armo Biosciences Questions
Armo Biosciences's website is http://www.armobio.com/index.php
Armo Biosciences's LinkedIn profile is https://www.linkedin.com/company/armo-bio
Armo Biosciences's industry is
Biotechnology
Armo Biosciences's top competitors are
Denali Therapeutics,
Alebund Pharmaceuticals,
Binacea Pharma,
Tenaya Therapeutics,
和誉医药,
Optra Ventures,
Pact Pharma,
Oric Pharmaceuticals Inc.,
Lexinto Biosolutions,
Libby Laboratories Inc.
Armo Biosciences's categories are Biotechnology
Armo Biosciences's founding year is 2012
